BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28795417)

  • 1. Molecular pathogenesis of human prostate basal cell hyperplasia.
    Henry G; Malewska A; Mauck R; Gahan J; Hutchinson R; Torrealba J; Francis F; Roehrborn C; Strand D
    Prostate; 2017 May; 77(13):1344-1355. PubMed ID: 28795417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
    Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
    Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface CD24 distinguishes between low differentiated and transit-amplifying cells in the basal layer of human prostate.
    Petkova N; Hennenlotter J; Sobiesiak M; Todenhöfer T; Scharpf M; Stenzl A; Bühring HJ; Schwentner C
    Prostate; 2013 Oct; 73(14):1576-90. PubMed ID: 23836489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating spatial transcriptomics and single-cell RNA-sequencing reveals the alterations in epithelial cells during nodular formation in benign prostatic hyperplasia.
    Fei X; Liu J; Xu J; Jing H; Cai Z; Yan J; Wu Z; Li H; Wang Z; Shen Y
    J Transl Med; 2024 Apr; 22(1):380. PubMed ID: 38654277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Expression Profiling Revealed 2 Types of Bronchial Basal Cell Hyperplasia and Squamous Metaplasia With Different Progression Potentials.
    Denisov EV; Schegoleva AA; Gerashchenko TS; Skryabin NA; Sleptcov AA; Yakushina VD; Lyapunova LS; Tuzikov SA; Pankova OV; Perelmuter VM
    Appl Immunohistochem Mol Morphol; 2020 Jul; 28(6):477-483. PubMed ID: 30896548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-to-mesenchymal transition and estrogen receptor α mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia.
    Shao R; Shi J; Liu H; Shi X; Du X; Klocker H; Lee C; Zhu Y; Zhang J
    Prostate; 2014 Jun; 74(9):970-82. PubMed ID: 24752964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell RNA sequencing of human prostate basal epithelial cells reveals zone-specific cellular populations and gene expression signatures.
    Vellky JE; Wu Y; Moline D; Drnevich J; Maienschein-Cline M; Valyi-Nagy K; Kajdacsy-Balla A; Vander Griend DJ
    J Pathol; 2024 Feb; 262(2):212-225. PubMed ID: 37984408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unusual morphologic patterns of basal cell hyperplasia of the prostate.
    Rioux-Leclercq NC; Epstein JI
    Am J Surg Pathol; 2002 Feb; 26(2):237-43. PubMed ID: 11812946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential gene expression profiling of functionally and developmentally distinct human prostate epithelial populations.
    Liu H; Cadaneanu RM; Lai K; Zhang B; Huo L; An DS; Li X; Lewis MS; Garraway IP
    Prostate; 2015 May; 75(7):764-76. PubMed ID: 25663004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis.
    Luo J; Dunn T; Ewing C; Sauvageot J; Chen Y; Trent J; Isaacs W
    Prostate; 2002 May; 51(3):189-200. PubMed ID: 11967953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of squamous cell lung carcinoma is associated with the co-presence of reactive lesions in tumor-adjacent bronchial epithelium.
    Pankova OV; Denisov EV; Ponomaryova AA; Gerashchenko TS; Tuzikov SA; Perelmuter VM
    Tumour Biol; 2016 Mar; 37(3):3599-607. PubMed ID: 26456960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression.
    Hudson DL; Guy AT; Fry P; O'Hare MJ; Watt FM; Masters JR
    J Histochem Cytochem; 2001 Feb; 49(2):271-8. PubMed ID: 11156695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
    Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
    Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
    Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
    Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal cell hyperplasia: an unusual diagnostic dilemma on prostate needle biopsies.
    Hosler GA; Epstein JI
    Hum Pathol; 2005 May; 36(5):480-5. PubMed ID: 15948114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical basal cell hyperplasia of the prostate. Immunophenotypic profile and proposed classification of basal cell proliferations.
    Devaraj LT; Bostwick DG
    Am J Surg Pathol; 1993 Jul; 17(7):645-59. PubMed ID: 7686348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
    Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
    Bonkhoff H; Remberger K
    Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.